2Sublicensing. (a) Dogwood may sublicense the rights granted to it under Section 2.1, through one or more tiers; provided that (i) as of the date of each proposed Sublicense this Agreement has not been terminated, (ii) the Sublicense is in writing; and (iii) the terms of the Sublicense are in accordance with the terms and conditions of this Agreement. Exclusive License Agreement6 CONFIDENTIAL (b) Dogwood will be responsible to Serpin for acts and omissions of its Sublicensees and the performance of any obligations of Sublicensees relevant to this Agreement as if such performance were carried out by Dogwood itself. (c) Each Sublicense shall contain a right of termination by Dogwood for the Sublicensee’s breach of any terms or conditions of the Sublicense that are also set forth, in substance, in this Agreement, which breach would constitute a breach of this Agreement if Dogwood failed to comply therewith. In the event of a Sublicensee breach of these obligations, and if after a reasonable cure period provided in the Sublicense the Sublicensee fails to cure the Sublicensee breach, then Dogwood shall terminate the Sublicense by written notice to the Sublicensee.
Appears in 2 contracts
Sources: Exclusive License Agreement (Dogwood Therapeutics, Inc.), Exclusive License Agreement (Dogwood Therapeutics, Inc.)